GlassScriptPhysician profile
Saramma George
NPI 1215035845
$3,085.08
in general payments reported to CMS, 2019-2025
26 companies · $615 in 2025
The $615 reported for 2025 was more than what 84% of Geriatric Medicine (Family Medicine) providers received nationally (typical 2025 total: $119).
See the full distribution for Geriatric Medicine (Family Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $278 · 2020: $79.19 · 2021: $309 · 2022: $416 · 2023: $560 · 2024: $828 · 2025: $615.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,003.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,003.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $698.45 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $373.88 | 2022-2025 | |
| Glaxosmithkline, LLC. | $307.72 | 2019-2025 | Trelegy Ellipta, Shingrix, Boostrix |
| Abbott Laboratories | $282.97 | 2019-2025 | Proclaim, Freestyle Libre 3, Eterna |
| Amgen INC. | $249.81 | 2021-2025 | Repatha, Otezla, Evenity |
| Lilly USA, LLC | $173.42 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $145.17 | 2021-2025 | Farxiga, Airsupra |
| Dexcom, INC. | $133.08 | 2023-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $105.98 | 2021-2023 | Jardiance |
| Astellas Pharma US INC | $103.80 | 2019-2024 | Veozah |
| Abbvie INC. | $83.09 | 2021-2024 | |
| Allergan, INC. | $71.03 | 2019-2020 | |
| Inspire Medical Systems, INC. | $63.01 | 2025 | Inspire |
| Exact Sciences Corporation | $41.31 | 2023 | Cologuard Collection Kit |
| Radius Health, INC. | $36.53 | 2020-2023 | Tymlos |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $31.85 | 2021 | |
| Merck Sharp & Dohme LLC | $28.50 | 2019-2022 | |
| Esperion Therapeutics, INC. | $25.38 | 2021 | |
| Ibsa Pharma INC. | $20.07 | 2023 | Tirosint, Licart |
| Horizon Therapeutics Plc | $19.54 | 2022 | |
| Axonics, INC. | $18.38 | 2020 | |
| Medtronic USA, INC. | $17.79 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.16 | 2023 | |
| Tms Neurohealth Centers INC. | $13.55 | 2025 | Tms Neurohealth Centers INC. |
| Janssen Pharmaceuticals, INC | $13.40 | 2020 | |
| Sanofi-Aventis U.S. LLC | $11.21 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saramma George listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.